Table 2

Indications for progression to anti-TNFα therapy

AgeM/FReason for stopping AZP/allopurinol
59MIntolerant of allopurinol taste
70FNausea and vomiting
33FDisease progression
23FDisease progression
27FDisease progression
36MLoss of appetite
66FNausea and vomiting
85MDisease progression
35FDisease progression
60MDisease progression
28FWeight gain*
  • *Patient reported weight gain with LDTA and for this reason ceased LDTA and required escalation to anti-TNFα.

  • AZP, azathioprine; LDTA, low dose thiopurine and allopurinol.